Unique ID issued by UMIN | UMIN000012486 |
---|---|
Receipt number | R000014615 |
Scientific Title | Granulocyte colony-stimulating factor-mediated pain relieving therapy for spinal cord lesion-related neuropathic pain syndrome: a prospective, single-blinded, placebo controlled, dose-response trial |
Date of disclosure of the study information | 2014/01/22 |
Last modified on | 2019/03/07 14:41:46 |
Granulocyte colony-stimulating factor-mediated pain relieving therapy for spinal cord lesion-related neuropathic pain syndrome: a prospective, single-blinded, placebo controlled, dose-response trial
G-CSF therapy for spinal cord lesion-related neuropathic pain
Granulocyte colony-stimulating factor-mediated pain relieving therapy for spinal cord lesion-related neuropathic pain syndrome: a prospective, single-blinded, placebo controlled, dose-response trial
G-CSF therapy for spinal cord lesion-related neuropathic pain
Japan |
spinal cord lesion-related neuropathic pain syndrome
Orthopedics |
Others
NO
The purpose of the present trial is to elucidate therapeutic effect and optimal dose of granulocyte colony-stimulating factor for spinal cord lesion-related neuropathic pain.
Safety,Efficacy
Exploratory
Phase II
Pain reduction 1 month after drug administration (evaluated by numerical rating scale)
1. ratio of the patients showing 30% or 50% pain reduction 1 month after drug administration
2. Alteration of the score of Neuropathic pain symptoms inventory
3. Quantitative evaluation for neuropathic pain
4. QOL measure (EQ-5D)
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Placebo
YES
3
Treatment
Medicine |
Granulocyte colony-stimulating factor (5 micro g/kg/d dissolved in 100ml of normal saline for 5 days, div.)
Granulocyte colony-stimulating factor (10 micro g/kg/d dissolved in 100ml of normal saline for 5 days, div.)
normal saline 100ml for 5 days
20 | years-old | <= |
85 | years-old | >= |
Male and Female
1. Spinal cord lesion-related neuropathic pain patients with at least 3 Months history.
2. Patients who did not respond conventional drug treatments.
3. Patients who are not scheduled for spinal surgery.
4. Definitive image or history of spinal cord lesions.
5. Patients who agree with the participation in the present trial with printed informed consent.
6. Patients who can participate the present trial for 6 Month.
1. Allergy for drugs to be tested.
2. History of hematologic malignancy.
3. Recent history (~5 years) of malignant disease.
4. Acute myocardial infarction or angina pectoris under treatment.
5. History or tendency of thorombosis or thoromboembolism.
6. Splenomegary.
7. Consciousness diorder.
8. Pregnancy.
60
1st name | |
Middle name | |
Last name | Masao Koda |
Chiba University Graduate School of Medicine
Department of Orthopedics
1-8-1 Inohana, Chuo-ku
043-226-2961
masaokod@gmail.com
1st name | |
Middle name | |
Last name | Yukiko Matsumoto |
Chiba University Graduate School of Medicine
Department of Orthopedics
1-8-1 Inohana, Chuo-ku
043-226-2961
chibaseikei8f@yahoo.co.jp
Chiba University Hospiotal
Ministry of Health, Labor and Welfare
Japanese Governmental office
Japan
NO
千葉大学医学部附属病院
2014 | Year | 01 | Month | 22 | Day |
Unpublished
Completed
2014 | Year | 04 | Month | 30 | Day |
2014 | Year | 05 | Month | 12 | Day |
2016 | Year | 01 | Month | 26 | Day |
2019 | Year | 02 | Month | 19 | Day |
2019 | Year | 02 | Month | 26 | Day |
2013 | Year | 12 | Month | 04 | Day |
2019 | Year | 03 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014615